{"protocolSection":{"identificationModule":{"nctId":"NCT06482099","orgStudyIdInfo":{"id":"C3671015"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS","officialTitle":"Special Investigation for ABRYSVO Intramuscular Injection -Investigation in Pregnant Women and Infants-"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-31","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-04-24","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-04-24","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-26","studyFirstSubmitQcDate":"2024-06-26","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-26","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This post-marketing study is a multicenter cohort study in pregnant women vaccinated with Abrysvo (RSV vaccineï¼‰designed to confirm the safety in pregnant women and their infants under actual clinical practice in Japan."},"conditionsModule":{"conditions":["Respiratory Tract Infection"],"keywords":["Respiratory Tract infection","RSV Vaccine","Maternal","Infant","Post Marketing Study"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":490,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"RSVpreF vaccine","description":"Pregnant women who have been vaccinated with Abrysvo for the first time.","interventionNames":["Biological: RSVpreF vaccine"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF vaccine","description":"Injection in the muscle, 1 dose 0.5mL","armGroupLabels":["RSVpreF vaccine"],"otherNames":["Abrysvo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of pregnant women reporting Adverse Reactions for 28 days after vaccination","timeFrame":"up to 28 days after vaccination"},{"measure":"Percentage of pregnant women reporting Serious Adverse Reactions from the day of vaccination up to 28 days after delivery","timeFrame":"up to 28 days after delivery"},{"measure":"Percentage of pregnant women reporting reactogenicity events (local reactions and systemic events) from day of vaccination up to 7 days after vaccination","timeFrame":"up to 7 days after vaccination"},{"measure":"Percentage of infants reporting Adverse Reactions from the birthday up to 28 days after birth","timeFrame":"up to 28 days after birth"},{"measure":"Percentage of infants reporting Serious Adverse Reactions from the birthday up to 28 days after birth","timeFrame":"up to 28 days after birth"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Pregnant women who have been vaccinated with Abrysvo for the first time after Abrysvo is launched. Pregnant women who have previously participated in the clinical trials of Abrysvo will be excluded.\n2. Vaccinated participants who have provided written consent regarding their participation in the study and entry of symptoms to ePRO with the use of their devices (smartphones, tablets PC, etc.) (or paper-PRO if there is any compelling reason) upon understanding the explanatory document. For a minor vaccinated participant, the parent(s) or legally acceptable representatives shall provide written consent.\n3. Pregnant women who have provided written consent to the participation of their infants in the study. For a minor vaccinated participant, the parent(s) or legally acceptable representatives shall provide written consent.\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study.","healthyVolunteers":true,"sex":"FEMALE","genderBased":true,"genderDescription":"Pregnant women","minimumAge":"0 Years","maximumAge":"99 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"Pregnant women who have been vaccinated with Abrysvo for the first time and their infants.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Pfizer CT.gov Call Center","role":"CONTACT","phone":"1-800-718-1021","email":"ClinicalTrials.gov_Inquiries@pfizer.com"}],"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer","city":"Tokyo","zip":"151-8589","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C3671015"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000012141","term":"Respiratory Tract Infections"}],"ancestors":[{"id":"D000007239","term":"Infections"},{"id":"D000012140","term":"Respiratory Tract Diseases"}],"browseLeaves":[{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M14978","name":"Respiratory Tract Infections","asFound":"Respiratory Tract Infections","relevance":"HIGH"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M17360","name":"Vaccines","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}